ArticleCancer medicine2026
Integrative Transcriptomic Signature of tRNA-Derived Fragment Targets and Lactylation-Related Genes for Prostate Cancer Diagnosis.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundConventional diagnostic strategies for prostate cancer (PCa) are hindered by suboptimal specificity, frequently resulting in overdiagnosis and unnecessary invasive biopsies. We developed an integrative diagnostic framework based on transcriptomic signatures from tRNA-derived fragments (tRFs), target genes, and lactylation-related genes (LRGs), two emerging regulators linked to PCa progression.
methodsBulk RNA-seq data from TCGA-PCa (499 tumors, 52 normals) and five independent GEO cohorts were analyzed. Differentially expressed genes (DEGs) were identified using edgeR and subsequently assessed for functional enrichment. Candidate markers were obtained by intersecting DEGs with predicted tRFs targets and curated LRGs. A least absolute shrinkage and selection operator (LASSO) model was trained and validated across external cohorts. RT-qPCR performed clinical confirmation in 30 prostate tissue samples.
resultsEleven genes overlapped among DEGs, tRF targets, and LRGs, and a seven-gene diagnostic signature (CSRP1, HMGN4, CALM1, NEFL, MSN, MKI67, ARID3A) was established. The model showed robust performance across all validation datasets, with AUC values of 0.728-0.904, exceeding those of prostate-specific antigen (PSA) testing. RT-qPCR supported significant dysregulation of five signature genes in clinical samples, notably decreased NEFL and increased MKI67. Decision curve analysis (DCA) suggested the model could reduce unnecessary biopsies by about 30% at commonly used clinical thresholds.
conclusionThis integrative model, incorporating tRFs-associated targets and lactylation-related signatures, demonstrates superior PCa detection accuracy compared to conventional PSA testing. The seven-gene signature offers a biologically informed, clinically applicable tool to improve early diagnosis while potentially reducing unnecessary biopsies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.